Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities in Canada and internationally. Its natural psilocybin is used for the long-term treatment of psychological trauma and its mental health consequences. The company also engages in developing therapeutic, hallucinogenic and subhallucinogenic dosing, and treatment protocols for the treatment of anxiety, depression, PTSD, grief, and bereavement. In addition, it focuses on the development of over-the-counter IP protected nutraceutical products for mental wellbeing. The company has a collaboration agreement with Scientific Research Council of Jamaica for psilocybin product development. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.12    OTCQB
As of 03/23/2023     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Index country:  Canada
Country of incorporation:  
IPO date:  01/04/2022
Outstanding shares:  103,852,103
Average volume:  385
Market cap:   $12,078,000
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy